A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer.
Charu AggarwalAlisha P MaityJoshua M BaumlQi LongTomas S AlemanChristine CiunciChristopher D'AvellaMelissa VolpeEvan AndersonLisa Mc Cormick JonesLova L SunAditi P SinghMelina E MarmarelisRoger B CohenCorey J LangerRavi K AmaravadiPublished in: The oncologist (2023)
The combination of B + HCQ in second- or later-line treatment of patients with advanced KRAS-mutant NSCLC did not show significant antitumor activity. (ClinicalTrials.gov Identifier: NCT04735068).